Homocysteine and Venous Thrombosis

ABSTRACT

Elevated plasma total homocysteine concentration is a risk factor for venous thrombosis. The association is well established in patients with homocystinuria irrespective of the genetic etiology and metabolic background. Homocystinuria is a human model of chronic exposure to very high concentrations of plasma homocysteine and reflects an abnormal amino acid metabolism. Elevated homocysteine levels in patients with venous thrombosis have attracted considerable interest because homocysteine is a potentially reversible thrombophilic marker for venous thrombosis. In contrast to homocystinuria, hyperhomocysteinemia is mild and reflects environmental and constitutional factors such as age, intake of B-vitamins, derangements of metabolism, and renal impairment. This review examines the evidence for the relationship of homocysteine with risk of venous thrombosis in homocystinuria and in the general population.

Homocysteine - homocystinuria - venous thromboembolism - children - elderly - MTHFR

REFERENCES

• 1 Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population.  J Intern Med. 1992;  232 155-160
• 2 Hansson P O, Werlin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population.  Arch Intern Med. 1997;  157 1665-1670
• 3 Heit J A, Silverstein M D, Mohr D N et al.. The epidemiology of venous thromboembolism in the community.  Thromb Haemost. 2001;  86 452-463
• 4 Mellemkjaer L, Sorensen H T, Dryere L, Olsen J, Olsen J H. Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark 1977-1995.  BMJ. 1999;  319 820-821
• 5 Chan A K, Deveber G, Monagle P, Brookers L A, Massicottes P M. Venous thrombosis in children.  J Thromb Haemost. 2003;  1 1443-1455
• 6 Homocysteine Lowering Trialist's Collaboration . Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials.  BMJ. 1998;  316 894-898
• 7 Ehrenforth S, Junker R, Koch H G, Kreuz W, Müchow N, Scharrer I. Nowak-Göttl U for the Childhood Thrombophilia Study Group.  Eur J Pediatr. 1999;  158 S97-S104
• 8 van Ommen C H, Heijboer H, Büller H R, Hirasing R A, Heijmans H SA, Peters M. Venous thromboembolism in childhood: a prospective 2-year registry in the Netherlands.  J Pediatr. 2001;  139 676-681
• 9 Lawson S E, Butler D, Williams M D. Congenital thrombophilia and thrombosis: a study in a single centre.  Arch Dis Child. 1999;  81 176-178
• 10 Tormene D, Simioni P, Prandoni P et al.. The incidence of venous thromboembolism in thrombophilic children: a prospective cohort study.  Blood. 2002;  100 2403-2405
• 11 Mudd S H, Skovby F, Levy H L et al.. The natural history of homocystinuria due to cystathionine beta-synthase deficiency.  Am J Hum Gene. 1985;  37 1-31
• 12 Cochran F B, Sweetman L, Schmidt K, Barsch G, Kraus J, Packman S. Pyridoxine-unresponsive homocystinuria with an unusual clinical course.  Am J Med Genet. 1990;  35 519
• 13 Sanson B JS, Simioni P, Tormene D et al.. The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of Antithrombin, Protein C or Protein S: a prospective cohort study.  Blood. 1999;  94 3702-3706
• 14 Simioni P, Sanson B J, Prandoni P et al.. Incidence of venous thromboembolism in families with inherited thrombophilia.  Thromb Haemost. 1999;  81 198-202
• 15 Buller H, Agnelli G, Hull R D, Prins M H, Raskob G E. Antithrombotic therapy for venous thromboembolism disease: the seventh ACCP Conference on antithrombotic and thrombolytic therapy.  Chest. 2004;  126 410-428
• 16 Yap S, Boers G HJ, Wilcken B et al.. Vascular outcome in patients with homocystinuria due to CBS deficiency treated chronically. A multicenter observational study.  Arterioscler Thromb Vasc Biol. 2001;  21 2080-2085
• 17 Mandel H, Brenner B, Berant M et al.. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis.  N Engl J Med. 1996;  334(12) 763-768
• 18 Quere I, Lamarti H, Chadefaux-Vekemans B. Thrombophilia, homocystinuria, and mutation of the factor V gene.  N Engl J Med. 1996;  335(4) 289
• 19 Kluijtmans L A, Boers G H, Verbruggen B, Trijbels F J, Novakova I R, Blom H J. Homozygous cystathionine beta-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis.  Blood. 1998;  91(6) 2015-2018
• 20 Yap S, O'Donnell K A, O'Neill C, Mayne P D, Thornton P, Naughten E. Factor V Leiden (Arg506Gln), a confounding genetic risk factor but not mandatory for the occurrence of venous thromboembolism in homozygotes and obligate heterozygotes for cystathionine beta-synthase deficiency.  Thromb Haemost. 1999;  81(4) 502-505
• 21 Ogier de Baulny H, Gérard M, Saudubray J M, Zittoun J. Remethylation defects: guidelines for clinical diagnosis and treatment.  Eur J Padiatr. 1998;  157 S77-S83
• 22 Bodamer O AF, Rosenblatt D S, Appel S H, Beaudet A L. Adult-onset combined methylmalonic aciduria and homocystinuria.  Neurology. 2001;  56 1113
• 23 Gaustadness M, Rüdiger N, Rasmussen K, Ingerslev J. Familial thrombophilia associated with homozygosity for the Cystathionine-β synthase 833T→C mutation.  Arterioscler Thromb Vasc Biol. 2000;  20 1392-1395
• 24 Maclean K N, Gaustadness M, Oliveriusova J et al.. High homocysteine and thrombosis without connective tissue disorders are associated with a novel class of cystathionine-β synthase (CBS) mutations.  Hum Mutat. 2002;  19 641-655
• 25 Lievers K JA, Kluijtmans L AJ, Blom H J. Genetics of hyperhomocysteinemia in cardiovascular disease.  Ann Clin Biochem. 2003;  40 46-59
• 26 Refsum H, Smith A D, Ueland P M et al.. Facts and recommendations about total homocysteine determinations: an expert opinion.  Clin Chem. 2004;  50 3-32
• 27 Tallova J, Tomandl J, Bicikova M, Hill M. Changes of plasma total homocysteine levels during the menstrual cycle.  Eur J Clin Invest. 1999;  29 1041-1044
• 28 Murphy M M, Scott J M, McPartlin J M, Fernandez-Ballart J D. The pregnancy-related decrease in fasting plasma homocysteine is not explained by folic acid supplementation, hemodilution or a decrease in albumin in a longitudinal study.  Am J Clin Nutr. 2002;  76 614-619
• 29 Morris M S, Jacques P F, Selhub J, Rosenberg I H. Total homocysteine and estrogen status in the Third National Health and Nutrition Examination Survey.  Am J Epidemiol. 2000;  152 140-148
• 30 Lacut K, Ogier E, Abalain J H, Moineau M P. Mottier D on behalf of the SARAH Investigators. Effects of oral and transdermal 17 β estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomised placebo-controlled trial.  Atherosclerosis. 2004;  174 173-180
• 31 Giri S, Thompson P D, Taxel P. Oral estrogen improves serum lipids, homocysteine and fibrinolysis in elderly men.  Atherosclerosis. 1998;  137 359
• 32 Giltay E J, Hoogeven E K, Elbers J MH, Goore L JG, Asscheman H, Stehouwer C DA. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females.  J Clin Endocrinol Metab. 1998;  83 550-553
• 33 Martinelli I, Battaglioli P, Pedotti P, Cattaneo M, Mannucci P M. Hyperhomocysteinemia and cerebral vein thrombosis.  Blood. 2003;  102 1363-1366
• 34 Lahey J M, Kearney J J, Tunc M. Hypercoagulable states and central vein occlusion.  Curr Opin Pulm Med. 2003;  9 385-392
• 35 Brattstrom L, Tengborn L, Lagerstedt C et al.. Plasma homocysteine in venous thromboembolism.  Haemostasis. 1991;  21 51-57
• 36 Bienvenu T, Ankri A, Chadefaux B et al.. Plasma homocysteine assay in the exploration of thrombosis in young subjects.  Presse Med. 1991;  20 985-988
• 37 den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies.  J Thromb Haemost. 2005;  2 1-8
• 38 Egerton W, Silberberg J, Crooks R, Ray C, Xie L, Dudman N. Serial measures of plasma homocysteine after acute myocardial infarction.  Am J Cardiol. 1996;  77 759-751
• 39 Murùa A, Quintana I, Galarza C, Alfie J, Kordich L. Unsuspected hyperhomocysteinemia in chronically anticoagulated patients.  Blood Coagul Fibrinolysis. 2001;  12 79-80
• 40 Ridker P M, Hennekens C H, Selhub J, Miletich J P, Malinow M R, Stampfer M J. Interrelation of hyperhomocyst(e)inemia, factor V Leiden and risk of future venous thromboembolism.  Circulation. 1997;  95 1777-1782
• 41 Tsai A W, Cushman M, Tsai M Y et al.. Serum homocysteine, MTHFR and venous thromboembolism: longitudinal investigation of thromboembolism etiology (LITE).  Am J Hematol. 2003;  72 192-200
• 42 Eichinger S, Stümpflen A, Hirschl M et al.. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism.  Thromb Haemost. 1998;  80 566-569
• 43 Kluijtmans L AJ, Young I S, Boreham C A et al.. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults.  Blood. 2003;  101 2483-2488
• 44 Tsai M Y, Bignell M, Yang F, Welge B G, Graham K J, Hanson N Q. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine b-synthase and A2756G methionine synthase with lowered plasma homocysteine levels.  Atherosclerosis. 2000;  149 131-137
• 45 Zetterberg H, Coppola A, D’Angelo A, Mona P, Rymo L, Blennow R. No association between the MTHFR A1298C and transcobalamin C677T genetic polymorphisms and hyperhomocysteinemia in thrombotic disease.  Thromb Res. 2003;  108 127-131
• 46 Salomon O, Rosenberg N, Zivelin A et al.. Methionine synthase and methylenetetrahydrofolate reductase A1298C polymorphisms are not risk factors for idiopathic venous thromboembolism.  Hematol J. 2001;  2 38-41
• 47 Frosst P, Blom H J, Milos R et al.. A candidate genetic risk factor for vascular disease: a common mutation in methylene tetrahydrofolate reductase.  Nat Genet. 1995;  10 111-113
• 48 Hussemoer L L, Thomsen T F, Fenger M, Jorgensen H L, Jorgensen T. Contribution of thermolabile MTHF reductase variant to plasma homocysteine levels in healthy men and women. Inter(99).  Genet Epidemiol. 2003;  24 322-330
• 49 Wald D S, Law M, Morris J K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.  BMJ. 2002;  325 1202-1206
• 50 De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G. Interaction between hyperhomocysteinemia and Inherited Thrombophilic factors in venous Thromboembolism.  Sem Thromb Haemost. 2000;  26 305-311
• 51 Quere I, Perneger T V, Zittoun J et al.. Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study.  Lancet. 2002;  359 747-752
• 52 Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci P M. Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis.  Circulation. 2001;  104 2442-2446
• 53 D’Angelo Armando . The role of vitB12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the MTHFR gene. A case-control study of patients with early-onset thrombotic events.  Thromb Haemost. 2000;  83 563-570
• 54 Marcucci R, Brunelli T, Giusti B et al.. The role of cystene and homocysteine in venous and arterial thrombotic disease.  Am J Clin Pathol. 2001;  116 56-60
• 55 den Heijer M, Brouwer I A, Bos G MJ et al.. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers.  Arterioscl Thromb Vasc Biol. 1998;  18 356-261
• 56 Willems H PJ, den Heijer M, Bos G MJ. Homocysteine and venous thrombosis: outline of a vitamin Intervention Trial.  Semin Thromb Haemost. 2000;  26 297-304